| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3332088 | Hematology/Oncology Clinics of North America | 2007 | 10 Pages |
Abstract
It is important when treating a patient who has advanced breast cancer to establish the biologic characteristics of the tumor. In addition to knowing the hormone receptor status (estrogen and progesterone), human epidermal receptor 2 (HER2) should be evaluated. The measurement of this parameter is essential to optimizing the systemic management. This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Nicholas J. MD, Anne M. MD,